



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the Application of:
Kenneth Brasel, et al.

Docket No.: 2836-D

Group Art Unit: 1644

Serial No: 09/448,378

Examiner: F.P.
VanderVegt

Filed: November 23, 1999

For: DENDRITIC CELL STIMULATORY FACTOR

1644 #7/0
RECEIVED
MAY 07 2001
TECH CENTER 1600/2900

Assistant Commissioner for Patents
Washington, D.C. 20231

AMENDMENT AND REPLY

Dear Sir:

In response to the second and Final Office action, having a mailing date of January 30, 2001, Applicants respectfully submit the following Amendment and Reply. Although after Final, Applicants kindly request the Examiner's discretion in amending the subject application as follows:

In the Claims:

6. (Twice amended) A method for augmenting an immune response in a patient having a cancerous or neoplastic disease, comprising the steps of administering flt3-ligand in an amount sufficient to generate an increase in the number of the patient's dendritic cells and administering **a tumor** antigen to the patient, **wherein the tumor antigen is expressed in the patient's cancerous or neoplastic tissues.**

20. (Twice amended) A method of treating cancerous or neoplastic disease in a patient in need thereof comprising administering Flt3-L in an amount sufficient to enhance the patient's immune response to such disease and administering **a tumor**

DO NOT
ENTER
5/25/01
R